Centre for Pharmacology and Toxicology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Stem Cell Rev Rep. 2021 Aug;17(4):1215-1238. doi: 10.1007/s12015-020-10114-6. Epub 2021 Jan 11.
Over the last decade research on cancer stem cells (CSC) significantly contributed to a better understanding of tumor biology. Given their similarity to normal stem cells, i.e. self-renewal and pluripotency the need arises to develop robust protocols for the isolation and characterization of CSCs. As with other malignancies, hepatic tumors are composed of a heterogeneous population of cells including liver cancer stem cells (LCSC). Yet, a precise understanding of why stem cells become cancerous is still lacking. There is unmet need to develop robust protocols for the successful isolation of LCSCs from human tissue resection material as to assist in the development of molecular targeted therapies. Here we review the research progress made in the isolation and characterization of LCSCs by considering a wide range of cell surface markers and sorting methods, as applied to side populations, microsphere cultures and the gradient centrifugation method. We emphasize the different fluorescence activated cell sorting methods and the possibility to enrich LCSCs by immunomagnetic beads. We review the specificity of functional assays by considering ABCG transporter and ALDH1 enzyme activities and evaluate the in vivo tumorigenicity of LCSCs in highly sensitive bioassays. Finally, we evaluate different LCSC markers in association with viral and non-viral liver disease and explore the potential of novel drug delivery systems targeting CD133, EpCAM, CD13 and CD90 for the development of molecular targeted therapies. Graphical Abstract.
在过去的十年中,癌症干细胞(CSC)的研究极大地促进了对肿瘤生物学的理解。鉴于它们与正常干细胞的相似性,即自我更新和多能性,因此需要开发用于分离和鉴定 CSC 的稳健方案。与其他恶性肿瘤一样,肝肿瘤由包括肝癌干细胞(LCSC)在内的异质细胞群体组成。然而,对于为什么干细胞会癌变,仍然缺乏确切的认识。因此,迫切需要开发稳健的方案,从人组织切除材料中成功分离 LCSC,以协助开发分子靶向疗法。在这里,我们通过考虑广泛的细胞表面标志物和分选方法,综述了 LCSC 的分离和鉴定研究进展,这些方法适用于侧群、微球体培养和梯度离心法。我们强调了不同的荧光激活细胞分选方法和通过免疫磁珠富集 LCSC 的可能性。我们通过考虑 ABCG 转运蛋白和 ALDH1 酶活性来评估功能测定的特异性,并在高度敏感的生物测定中评估 LCSC 的体内致瘤性。最后,我们评估了与病毒和非病毒肝病相关的不同 LCSC 标志物,并探索了针对 CD133、EpCAM、CD13 和 CD90 的新型药物输送系统靶向 LCSC 的潜力,以开发分子靶向疗法。